Naloxone Cloridrato Bambini S.A.L.F. (Naloxone Hydrochloride Dihydrate)

Naloxone Hydrochloride Dihydrate, the active ingredient in Naloxone Cloridrato Bambini S.A.L.F., is an opioid antagonist presented as an injectable solution for intramuscular, intravenous, and subcutaneous use. It rapidly reverses the effects of opioid overdose and opioid‑induced respiratory depression in emergency settings. It is formulated for rapid administration by healthcare professionals in acute care environments.

GNH USA supplies Naloxone Cloridrato Bambini S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is packaged in sealed vials.

Naloxone, an opioid antagonist, is used to counteract opioid toxicity and associated respiratory depression.

- Opioid overdose: rapid restoration of normal breathing and consciousness. - Opioid‑induced respiratory depression: reversal of depressed ventilation in clinical settings. - Opioid toxicity after procedural sedation: immediate antagonism of opioid effects to prevent respiratory compromise.

Naloxone may be associated with a range of adverse reactions, most of which are transient and related to abrupt opioid withdrawal.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional emesis after administration. - Sweating: increased perspiration. - Tremor: involuntary shaking. - Anxiety: heightened nervousness. - Headache: mild cranial pain.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm. - Seizure: convulsive episodes. - Severe hypertension: sudden high blood pressure. - Pulmonary edema: fluid accumulation in lungs. - Anaphylaxis: life‑threatening allergic reaction.

When using naloxone, healthcare providers should observe specific precautions to ensure safety and effectiveness. - Patient assessment: confirm opioid overdose before administration. - Cardiovascular monitoring: observe heart rate and blood pressure after reversal. - Re‑dosing: be prepared to repeat dose if opioid effect persists. - Concomitant opioid use: consider that long‑acting opioids may require additional doses. - Pregnancy and lactation: use only if benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Naloxone can interact with other substances, influencing its efficacy or safety profile.

Major Interactions (Avoid): - High‑dose opioid agonists: may overwhelm naloxone effect, requiring higher or repeated dosing. - MAO inhibitors: combined use may increase risk of hypertensive crisis after opioid reversal. - Tricyclic antidepressants: may potentiate seizures when opioid withdrawal occurs.

Moderate Interactions (Monitor Closely): - Benzodiazepines: concurrent use can mask withdrawal symptoms, requiring careful monitoring. - Alcohol: may exacerbate central nervous system depression after naloxone. - CNS stimulants: may increase risk of agitation during opioid reversal.